Pragmatic Randomized Controlled Trial of Pharmacopuncture Therapy for Adhesive Capsulitis : A Pilot Study
Study Details
Study Description
Brief Summary
This is a 2-arm parallel pragmatic randomized controlled trial that will compare pharmacopuncture therapy with physical therapy for adhesive capsulitis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Participants who voluntarily signed informed consent form and eligible for the study were randomly assigned in a 1:1 ratio (25:25) for pharmacopuncture therapy and physical therapy group. Participants of each group will receive twice a week for total 6 weeks of intervention. This is a pragmatic randomized controlled trial, so physicians will have medical decision making according to each participant's conditions.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: pharmacopunture therapy The physicians will choose the type and volume of pharmacopuncture according to participants' conditions and inject it at the proper acupoints they choose. |
Procedure: pharmacopuncture therapy
This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
|
| Active Comparator: physical therapy The physicians will choose the type and time of physical therapy according to participants' conditions. |
Procedure: physical therapy
This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
|
Outcome Measures
Primary Outcome Measures
- Numeric rating scale (NRS) of shoulder pain [week 7]
NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'.
Secondary Outcome Measures
- Visual analogue scale (VAS) of shoulder pain [week 1, 2, 3, 4, 5, 6, 7, 13]
Visual analogue scale of shoulder pain, minimum 0 to maximum 100, which is a higher score means a worse outcome.
- ROM(Range of motion) [week 1, 2, 3, 4, 5, 6, 7, 13]
The range of shoulder movement shows the function of the shoulder capsule.
- SPADI [week 1, 7, 13]
SPADI is a functional disability questionnaire. The possible range of each item score is 0 to 10. Total score range is 0 (better outcome) to 100 (worse outcome).
- PGIC [week 7, 13]
Participants rate the improvement after treatment on a 7-point Likert scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.)
- SF-12 v2 [week 1, 7, 13]
The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life.
- EQ-5D-5L [week 1, 7, 13]
The EQ-5D-5L consists of 5 questions (mobility, self-care, usual activities, pain, anxiety/depression) that ask about the current state of health, and answers each question with 5 likert. (1=I have no problems about, 2=I have slight problems about, 3=I have moderate problems about, 4=I have severe problems about, 5=I am unable to about)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Limitation of the shoulder movement (active or passive)
-
Numeric Rating Scale (NRS) of neck pain is more than 5
-
Symptoms of adhesive capsulitis for more than 1 month
-
Discrimination findings which can explain clinical symptoms on shoulder MRI or CT
-
19-69 years old
-
participants who agreed and wrote informed consents
Exclusion Criteria:
-
Case of being diagnosed with a specific serious disease that may cause shoulder pain(Fracture, Dislocation, etc.)
-
Cause of pain due to soft tissue disease, not the spine(Cancer, fibromyalgia, RA, goat, or etc.) Other chronic diseases(stroke, MI, kidney disease, diabetic neuropathy, dimentia, epilepsy, or etc.) that may interfere with the interpretation of therapeutic effects or outcomes
-
Participants taking steroid, immunosuppressant, psychotropic medication, or taking other drugs that may affect outcomes
-
Inappropriate or unsafe pharmacopuncture therapy; hemorrhagic disease, taking anticoagulant drug, or severe diabetes patients who are likely to be infected
-
Participants who took NSAIDs or pharmacopuncture, acupuncture, physical therapy within 1 week
-
Pregnant, planning to get pregnant or lactating women
-
Participants who had undergone shoulder surgery within 3 months
-
Participants who had participated in other clinical trial within 1 month, had participated in other study within 6 months from the date of selection, or have plan for participation in other trial during follow up period of this trial
-
Participants who can not write informed consent
-
Participants who is difficult to participate in the trial according to investigator's decision
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Jaseng Korean Medicine Hospital | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Jaseng Hospital of Korean Medicine
- Korea Institute of Oriental Medicine
Investigators
- Principal Investigator: Kyoung Sun Park, Ph.D, Jaseng Hospital of Korean Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JS-CT-2022-01